SK13292000A3 - Antagonisty vitronektínového receptora, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty - Google Patents

Antagonisty vitronektínového receptora, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty Download PDF

Info

Publication number: SK13292000A3
Authority: SK; Slovakia
Prior art keywords: alkyl; phenyl; pyridinyl; mmol; methylamino
Prior art date: 1998-03-10

Application number

SK1329-2000A

Other languages

English (en)

Slovak (sk)

Inventor

William H. Miller

John G. Gleason

Dirk Heerding

James M. Samanen

Irene N. Uzinskas

Peter J. Manley

Original Assignee

Smithkline Beecham Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-10

Filing date

1999-03-10

Publication date

2001-06-11

1999-03-10 Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation

2001-06-11 Publication of SK13292000A3 publication Critical patent/SK13292000A3/sk

Links

102100022337 Integrin alpha-V Human genes 0.000 title claims abstract description 63
108010048673 Vitronectin Receptors Proteins 0.000 title claims abstract description 63
239000002464 receptor antagonist Substances 0.000 title claims description 42
229940044551 receptor antagonist Drugs 0.000 title claims description 42
150000001875 compounds Chemical class 0.000 claims abstract description 356
238000011282 treatment Methods 0.000 claims abstract description 33
201000010099 disease Diseases 0.000 claims abstract description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
206010028980 Neoplasm Diseases 0.000 claims abstract description 19
208000001132 Osteoporosis Diseases 0.000 claims abstract description 12
208000037803 restenosis Diseases 0.000 claims abstract description 9
201000001320 Atherosclerosis Diseases 0.000 claims abstract description 8
206010061218 Inflammation Diseases 0.000 claims abstract description 6
230000004054 inflammatory process Effects 0.000 claims abstract description 6
-1 methylenedioxy Chemical group 0.000 claims description 179
238000000034 method Methods 0.000 claims description 98
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 68
229910052736 halogen Inorganic materials 0.000 claims description 48
229910002091 carbon monoxide Inorganic materials 0.000 claims description 46
150000002367 halogens Chemical class 0.000 claims description 45
229910052760 oxygen Inorganic materials 0.000 claims description 36
125000000217 alkyl group Chemical group 0.000 claims description 32
229910052786 argon Inorganic materials 0.000 claims description 29
229910052717 sulfur Inorganic materials 0.000 claims description 28
229910052799 carbon Inorganic materials 0.000 claims description 27
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
229910052739 hydrogen Inorganic materials 0.000 claims description 23
238000004519 manufacturing process Methods 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 21
125000003118 aryl group Chemical group 0.000 claims description 20
229910052757 nitrogen Inorganic materials 0.000 claims description 18
239000002246 antineoplastic agent Substances 0.000 claims description 17
125000006239 protecting group Chemical group 0.000 claims description 17
RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims description 16
229940034982 antineoplastic agent Drugs 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 15
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
125000000623 heterocyclic group Chemical group 0.000 claims description 13
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
102000005962 receptors Human genes 0.000 claims description 13
108020003175 receptors Proteins 0.000 claims description 13
125000001424 substituent group Chemical group 0.000 claims description 13
239000005557 antagonist Substances 0.000 claims description 12
239000008194 pharmaceutical composition Substances 0.000 claims description 12
125000002837 carbocyclic group Chemical group 0.000 claims description 11
230000002401 inhibitory effect Effects 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 10
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 9
230000004614 tumor growth Effects 0.000 claims description 9
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 8
229960004316 cisplatin Drugs 0.000 claims description 8
230000005764 inhibitory process Effects 0.000 claims description 8
206010065687 Bone loss Diseases 0.000 claims description 7
230000008569 process Effects 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
125000004076 pyridyl group Chemical group 0.000 claims description 6
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical group C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 6
229960000303 topotecan Drugs 0.000 claims description 6
230000033115 angiogenesis Effects 0.000 claims description 5
125000000524 functional group Chemical group 0.000 claims description 5
RNIAZYIULBLNOQ-UHFFFAOYSA-N 2-[2-phenoxy-4-[5-(pyridin-2-ylamino)pentoxy]phenyl]acetic acid Chemical compound C1=C(OC=2C=CC=CC=2)C(CC(=O)O)=CC=C1OCCCCCNC1=CC=CC=N1 RNIAZYIULBLNOQ-UHFFFAOYSA-N 0.000 claims description 4
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
206010027476 Metastases Diseases 0.000 claims description 4
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 4
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
IAMUMIBDQILHMZ-OAQYLSRUSA-N (3r)-3-phenyl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid Chemical compound C([C@H](CC(=O)O)C=1C=CC=CC=1)C(C=C1)=CC=C1OCCCNC1=CC=CC=N1 IAMUMIBDQILHMZ-OAQYLSRUSA-N 0.000 claims description 3
DTLIDYQJLOBQPK-QFIPXVFZSA-N (3s)-3-phenyl-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]butanoic acid Chemical compound C1([C@@H](CC=2C=CC(OCCC=3N=C4NCCCC4=CC=3)=CC=2)CC(=O)O)=CC=CC=C1 DTLIDYQJLOBQPK-QFIPXVFZSA-N 0.000 claims description 3
WCPSGCOZKAYILU-FQEVSTJZSA-N (3s)-3-phenyl-4-[4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)propoxy]phenyl]butanoic acid Chemical compound C([C@@H](CC(=O)O)C=1C=CC=CC=1)C(C=C1)=CC=C1OCCCNC1=NCCCN1 WCPSGCOZKAYILU-FQEVSTJZSA-N 0.000 claims description 3
IAMUMIBDQILHMZ-NRFANRHFSA-N (3s)-3-phenyl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid Chemical compound C([C@@H](CC(=O)O)C=1C=CC=CC=1)C(C=C1)=CC=C1OCCCNC1=CC=CC=N1 IAMUMIBDQILHMZ-NRFANRHFSA-N 0.000 claims description 3
URKJIXZWGSBZBB-INIZCTEOSA-N (3s)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(1,3-thiazol-2-yl)butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(C[C@@H](CC(O)=O)C=3SC=CN=3)=CC=2)=N1 URKJIXZWGSBZBB-INIZCTEOSA-N 0.000 claims description 3
QQEIIOWLNXVJET-FQEVSTJZSA-N (3s)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-phenylbutanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(C[C@@H](CC(O)=O)C=3C=CC=CC=3)=CC=2)=N1 QQEIIOWLNXVJET-FQEVSTJZSA-N 0.000 claims description 3
CVIPGYDGAAPSKL-UHFFFAOYSA-N 2-[benzyl-[[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]methyl]amino]acetic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CN(CC(O)=O)CC=3C=CC=CC=3)=CC=2)=N1 CVIPGYDGAAPSKL-UHFFFAOYSA-N 0.000 claims description 3
SDFOJSFWUHHYNZ-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3SC4=CC=CC=C4N=3)=CC=2)=N1 SDFOJSFWUHHYNZ-UHFFFAOYSA-N 0.000 claims description 3
VUHBUUPDUUVNKT-UHFFFAOYSA-N 3-(1h-imidazol-2-yl)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3NC=CN=3)=CC=2)=N1 VUHBUUPDUUVNKT-UHFFFAOYSA-N 0.000 claims description 3
VTXUWTXSNNOZQV-UHFFFAOYSA-N 3-[1-(dimethylsulfamoyl)imidazol-2-yl]-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3N(C=CN=3)S(=O)(=O)N(C)C)=CC=2)=N1 VTXUWTXSNNOZQV-UHFFFAOYSA-N 0.000 claims description 3
KKGRVRSAWMYXAX-UHFFFAOYSA-N 3-[[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]methyl]-5-phenylpentanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CCC=3C=CC=CC=3)CC(O)=O)=CC=2)=N1 KKGRVRSAWMYXAX-UHFFFAOYSA-N 0.000 claims description 3
FKIUJPKATZMXEU-UHFFFAOYSA-N 3-cyclopropyl-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C3CC3)=CC=2)=N1 FKIUJPKATZMXEU-UHFFFAOYSA-N 0.000 claims description 3
GQAGHOJOIIYQFT-UHFFFAOYSA-N 3-methyl-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(C)CC(O)=O)=CC=2)=N1 GQAGHOJOIIYQFT-UHFFFAOYSA-N 0.000 claims description 3
MWIDYJJFSZUTTH-UHFFFAOYSA-N 3-methyl-4-[4-[2-[6-(methylamino)pyridin-3-yl]ethoxy]phenyl]butanoic acid Chemical compound C1=NC(NC)=CC=C1CCOC1=CC=C(CC(C)CC(O)=O)C=C1 MWIDYJJFSZUTTH-UHFFFAOYSA-N 0.000 claims description 3
MNMNKSRAIMNXQS-UHFFFAOYSA-N 3-methyl-4-[4-[3-(pyridin-2-ylamino)propoxy]phenyl]butanoic acid Chemical compound C1=CC(CC(CC(O)=O)C)=CC=C1OCCCNC1=CC=CC=N1 MNMNKSRAIMNXQS-UHFFFAOYSA-N 0.000 claims description 3
ZYUAXXDJBBQPEQ-UHFFFAOYSA-N 3-phenyl-4-[4-[2-(pyridin-2-ylamino)ethylcarbamoyl]phenyl]butanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)CC(C=C1)=CC=C1C(=O)NCCNC1=CC=CC=N1 ZYUAXXDJBBQPEQ-UHFFFAOYSA-N 0.000 claims description 3
XOJKPSNTNATASA-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(1,3-oxazol-2-yl)butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3OC=CN=3)=CC=2)=N1 XOJKPSNTNATASA-UHFFFAOYSA-N 0.000 claims description 3
URKJIXZWGSBZBB-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(1,3-thiazol-2-yl)butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3SC=CN=3)=CC=2)=N1 URKJIXZWGSBZBB-UHFFFAOYSA-N 0.000 claims description 3
OZQLHJZFAHUBOG-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(4-methyl-1,3-thiazol-2-yl)butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3SC=C(C)N=3)=CC=2)=N1 OZQLHJZFAHUBOG-UHFFFAOYSA-N 0.000 claims description 3
SUEPPQJCLHQCOC-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(4-propan-2-ylphenyl)butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3C=CC(=CC=3)C(C)C)=CC=2)=N1 SUEPPQJCLHQCOC-UHFFFAOYSA-N 0.000 claims description 3
QQEIIOWLNXVJET-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-phenylbutanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3C=CC=CC=3)=CC=2)=N1 QQEIIOWLNXVJET-UHFFFAOYSA-N 0.000 claims description 3
AUMTZWYOTTZIPE-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-pyridin-2-ylbutanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3N=CC=CC=3)=CC=2)=N1 AUMTZWYOTTZIPE-UHFFFAOYSA-N 0.000 claims description 3
BUAVKXYCGMZUOY-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-thiophen-2-ylbutanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3SC=CC=3)=CC=2)=N1 BUAVKXYCGMZUOY-UHFFFAOYSA-N 0.000 claims description 3
DRKUZFAYZWOBOG-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]but-3-enoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(C=CCC(O)=O)=CC=2)=N1 DRKUZFAYZWOBOG-UHFFFAOYSA-N 0.000 claims description 3
KZLZCSIDMKXJRJ-UHFFFAOYSA-N 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CCCC(O)=O)=CC=2)=N1 KZLZCSIDMKXJRJ-UHFFFAOYSA-N 0.000 claims description 3
UMSOUUMTSPJKIP-UHFFFAOYSA-N 4-[4-[3-[(4-methylpyridin-2-yl)amino]propoxy]phenyl]-3-(4-propan-2-ylphenyl)butanoic acid Chemical compound C1=CC(C(C)C)=CC=C1C(CC(O)=O)CC(C=C1)=CC=C1OCCCNC1=CC(C)=CC=N1 UMSOUUMTSPJKIP-UHFFFAOYSA-N 0.000 claims description 3
229940078581 Bone resorption inhibitor Drugs 0.000 claims description 3
230000009401 metastasis Effects 0.000 claims description 3
OYHDUTMJLJKRQF-UHFFFAOYSA-N 2-[[2-methoxy-4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]methylamino]acetic acid Chemical compound CNC1=CC=CC(CCOC=2C=C(OC)C(CNCC(O)=O)=CC=2)=N1 OYHDUTMJLJKRQF-UHFFFAOYSA-N 0.000 claims description 2
FGWNMQZSNUKPFC-UHFFFAOYSA-N 3-benzyl-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)CC=3C=CC=CC=3)=CC=2)=N1 FGWNMQZSNUKPFC-UHFFFAOYSA-N 0.000 claims description 2
MVJOIQPJZKTESD-UHFFFAOYSA-N 3-methyl-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]but-3-enoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(C=C(C)CC(O)=O)=CC=2)=N1 MVJOIQPJZKTESD-UHFFFAOYSA-N 0.000 claims description 2
IAMUMIBDQILHMZ-UHFFFAOYSA-N 3-phenyl-4-[4-[3-(pyridin-1-ium-2-ylamino)propoxy]phenyl]butanoate Chemical compound C=1C=CC=CC=1C(CC(=O)O)CC(C=C1)=CC=C1OCCCNC1=CC=CC=N1 IAMUMIBDQILHMZ-UHFFFAOYSA-N 0.000 claims description 2
125000002883 imidazolyl group Chemical group 0.000 claims description 2
125000002971 oxazolyl group Chemical group 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
230000008485 antagonism Effects 0.000 claims 4
125000005843 halogen group Chemical group 0.000 claims 3
PFLLBMOLOVUVLP-SFHVURJKSA-N (3s)-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]-3-(1,3-thiazol-2-yl)butanoic acid Chemical compound C1([C@@H](CC=2C=CC(OCCC=3N=C4NCCCC4=CC=3)=CC=2)CC(=O)O)=NC=CS1 PFLLBMOLOVUVLP-SFHVURJKSA-N 0.000 claims 1
VEEBAWVYVGVHBT-UHFFFAOYSA-N 3-(furan-2-yl)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3OC=CC=3)=CC=2)=N1 VEEBAWVYVGVHBT-UHFFFAOYSA-N 0.000 claims 1
HCPRPQNWWRMIHG-UHFFFAOYSA-N 3-phenyl-3-[4-[4-(pyridin-2-ylamino)butyl]anilino]propanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)NC(C=C1)=CC=C1CCCCNC1=CC=CC=N1 HCPRPQNWWRMIHG-UHFFFAOYSA-N 0.000 claims 1
125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
238000011260 co-administration Methods 0.000 claims 1
208000006386 Bone Resorption Diseases 0.000 abstract description 11
230000024279 bone resorption Effects 0.000 abstract description 11
201000011510 cancer Diseases 0.000 abstract description 5
208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 338
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 288
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 280
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 263
239000000243 solution Substances 0.000 description 209
239000000203 mixture Substances 0.000 description 195
235000019439 ethyl acetate Nutrition 0.000 description 167
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 142
238000002360 preparation method Methods 0.000 description 137
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 120
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 109
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 107
239000003921 oil Substances 0.000 description 105
235000019198 oils Nutrition 0.000 description 105
239000000741 silica gel Substances 0.000 description 97
229910002027 silica gel Inorganic materials 0.000 description 97
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 96
239000011541 reaction mixture Substances 0.000 description 96
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 84
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 83
239000007787 solid Substances 0.000 description 72
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 69
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 66
210000004027 cell Anatomy 0.000 description 64
238000005481 NMR spectroscopy Methods 0.000 description 58
239000002904 solvent Substances 0.000 description 54
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 50
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 49
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 48
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical group [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 42
238000006243 chemical reaction Methods 0.000 description 40
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
230000002829 reductive effect Effects 0.000 description 38
210000002997 osteoclast Anatomy 0.000 description 34
229910052763 palladium Inorganic materials 0.000 description 34
238000010992 reflux Methods 0.000 description 34
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 33
239000012044 organic layer Substances 0.000 description 33
238000000746 purification Methods 0.000 description 33
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 32
239000000706 filtrate Substances 0.000 description 31
239000011734 sodium Substances 0.000 description 31
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
238000010898 silica gel chromatography Methods 0.000 description 29
235000002639 sodium chloride Nutrition 0.000 description 29
239000010410 layer Substances 0.000 description 27
239000000725 suspension Substances 0.000 description 27
238000004809 thin layer chromatography Methods 0.000 description 27
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 24
238000004587 chromatography analysis Methods 0.000 description 23
229920006395 saturated elastomer Polymers 0.000 description 23
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
239000007864 aqueous solution Substances 0.000 description 21
239000012230 colorless oil Substances 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 18
238000001035 drying Methods 0.000 description 18
239000000284 extract Substances 0.000 description 18
238000003818 flash chromatography Methods 0.000 description 18
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
239000002585 base Substances 0.000 description 17
239000000047 product Substances 0.000 description 17
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 17
229910000104 sodium hydride Inorganic materials 0.000 description 17
CLUBWMGIEFXAFU-UHFFFAOYSA-N 1-[6-(methylamino)pyridin-2-yl]ethanol Chemical compound CNC1=CC=CC(C(C)O)=N1 CLUBWMGIEFXAFU-UHFFFAOYSA-N 0.000 description 16
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 16
239000011324 bead Substances 0.000 description 16
239000000872 buffer Substances 0.000 description 16
229910001868 water Inorganic materials 0.000 description 16
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
150000001732 carboxylic acid derivatives Chemical class 0.000 description 15
LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 15
238000001914 filtration Methods 0.000 description 15
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
230000020477 pH reduction Effects 0.000 description 15
239000000843 powder Substances 0.000 description 15
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 15
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 14
150000001299 aldehydes Chemical class 0.000 description 13
230000027455 binding Effects 0.000 description 13
239000003153 chemical reaction reagent Substances 0.000 description 13
239000000543 intermediate Substances 0.000 description 13
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 13
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
239000012267 brine Substances 0.000 description 12
239000003054 catalyst Substances 0.000 description 12
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 12
239000006260 foam Substances 0.000 description 12
238000001802 infusion Methods 0.000 description 12
239000007788 liquid Substances 0.000 description 12
239000002609 medium Substances 0.000 description 12
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
239000002244 precipitate Substances 0.000 description 12
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 11
150000001412 amines Chemical class 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 11
238000005119 centrifugation Methods 0.000 description 11
150000002148 esters Chemical class 0.000 description 11
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 11
VNOXYDAAZVUZDS-UHFFFAOYSA-N ethyl 4-(4-hydroxyphenyl)-3-phenylbutanoate Chemical compound C=1C=CC=CC=1C(CC(=O)OCC)CC1=CC=C(O)C=C1 VNOXYDAAZVUZDS-UHFFFAOYSA-N 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 10
241000700159 Rattus Species 0.000 description 10
238000003556 assay Methods 0.000 description 10
239000012737 fresh medium Substances 0.000 description 10
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 10
239000012442 inert solvent Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
239000000463 material Substances 0.000 description 10
VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 10
238000005406 washing Methods 0.000 description 10
108091003079 Bovine Serum Albumin Proteins 0.000 description 9
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 9
239000012980 RPMI-1640 medium Substances 0.000 description 9
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 9
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
239000000010 aprotic solvent Substances 0.000 description 8
210000000988 bone and bone Anatomy 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
FTAPOXHOTLABPV-UHFFFAOYSA-N ethyl 4-(4-methoxyphenyl)-3-phenylbutanoate Chemical compound C=1C=CC=CC=1C(CC(=O)OCC)CC1=CC=C(OC)C=C1 FTAPOXHOTLABPV-UHFFFAOYSA-N 0.000 description 8
238000007429 general method Methods 0.000 description 8
238000011534 incubation Methods 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 7
125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
238000002965 ELISA Methods 0.000 description 7
101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 7
102100035140 Vitronectin Human genes 0.000 description 7
108010031318 Vitronectin Proteins 0.000 description 7
150000001408 amides Chemical class 0.000 description 7
229910052802 copper Inorganic materials 0.000 description 7
239000010949 copper Substances 0.000 description 7
239000003960 organic solvent Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 6
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 6
108010012088 Fibrinogen Receptors Proteins 0.000 description 6
208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 6
239000012979 RPMI medium Substances 0.000 description 6
102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 6
108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 6
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 6
239000011575 calcium Substances 0.000 description 6
239000006285 cell suspension Substances 0.000 description 6
KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 6
238000010494 dissociation reaction Methods 0.000 description 6
230000005593 dissociations Effects 0.000 description 6
VNOXYDAAZVUZDS-INIZCTEOSA-N ethyl (3s)-4-(4-hydroxyphenyl)-3-phenylbutanoate Chemical compound C([C@@H](CC(=O)OCC)C=1C=CC=CC=1)C1=CC=C(O)C=C1 VNOXYDAAZVUZDS-INIZCTEOSA-N 0.000 description 6
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 6
238000005984 hydrogenation reaction Methods 0.000 description 6
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
210000005087 mononuclear cell Anatomy 0.000 description 6
238000007911 parenteral administration Methods 0.000 description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
238000003756 stirring Methods 0.000 description 6
238000010189 synthetic method Methods 0.000 description 6
AEOKOTHPXHJDTN-UHFFFAOYSA-N tert-butyl n-[6-(1-hydroxyethyl)pyridin-2-yl]-n-methylcarbamate Chemical compound CC(O)C1=CC=CC(N(C)C(=O)OC(C)(C)C)=N1 AEOKOTHPXHJDTN-UHFFFAOYSA-N 0.000 description 6
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
UBQKLVRIDJPLPF-UHFFFAOYSA-N OCCCNC1=CC=CC=[N+]1[O-] Chemical compound OCCCNC1=CC=CC=[N+]1[O-] UBQKLVRIDJPLPF-UHFFFAOYSA-N 0.000 description 5
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 5
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 5
229940098773 bovine serum albumin Drugs 0.000 description 5
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
239000012043 crude product Substances 0.000 description 5
239000008121 dextrose Substances 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
XIQDIWRNORKSDX-UHFFFAOYSA-N ethyl 4-(4-hydroxyphenyl)-3-methylbutanoate Chemical compound CCOC(=O)CC(C)CC1=CC=C(O)C=C1 XIQDIWRNORKSDX-UHFFFAOYSA-N 0.000 description 5
239000012065 filter cake Substances 0.000 description 5
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
XGDZEDRBLVIUMX-UHFFFAOYSA-N methyl 2-(4-hydroxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C=C1 XGDZEDRBLVIUMX-UHFFFAOYSA-N 0.000 description 5
NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 5
238000002156 mixing Methods 0.000 description 5
YJGUUWHSAANPMU-UHFFFAOYSA-N n'-pyridin-2-ylethane-1,2-diamine;dihydrochloride Chemical compound Cl.Cl.NCCNC1=CC=CC=N1 YJGUUWHSAANPMU-UHFFFAOYSA-N 0.000 description 5
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
229910052697 platinum Inorganic materials 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 4
BLRCPDFGSIPXRC-UHFFFAOYSA-N 1-o-benzyl 4-o-methyl 2-methylidenebutanedioate Chemical compound COC(=O)CC(=C)C(=O)OCC1=CC=CC=C1 BLRCPDFGSIPXRC-UHFFFAOYSA-N 0.000 description 4
KIERUHADLUVNBV-UHFFFAOYSA-N 2-(4-phenylmethoxyphenyl)-1-(1,3-thiazol-2-yl)ethanone Chemical compound N=1C=CSC=1C(=O)CC(C=C1)=CC=C1OCC1=CC=CC=C1 KIERUHADLUVNBV-UHFFFAOYSA-N 0.000 description 4
BJIIQELUPDFDOI-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methyl]-4-phenylbutanoic acid Chemical compound C1=CC(OC)=CC=C1CC(C(O)=O)CCC1=CC=CC=C1 BJIIQELUPDFDOI-UHFFFAOYSA-N 0.000 description 4
RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 4
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 4
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical group OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 4
WBIZZNFQJPOKDK-UHFFFAOYSA-N 4-hydroxy-2-methoxybenzaldehyde Chemical compound COC1=CC(O)=CC=C1C=O WBIZZNFQJPOKDK-UHFFFAOYSA-N 0.000 description 4
125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 4
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 4
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
241000283086 Equidae Species 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
235000019502 Orange oil Nutrition 0.000 description 4
IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical compound CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
150000001336 alkenes Chemical class 0.000 description 4
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 4
229910052801 chlorine Inorganic materials 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 4
ZZLIOKTZZYRMGW-UHFFFAOYSA-N ethyl 2-[benzyl-[(4-hydroxyphenyl)methyl]amino]acetate Chemical compound C=1C=C(O)C=CC=1CN(CC(=O)OCC)CC1=CC=CC=C1 ZZLIOKTZZYRMGW-UHFFFAOYSA-N 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000007789 gas Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
239000002502 liposome Substances 0.000 description 4
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
OUWFDISHMBDYON-UHFFFAOYSA-N methyl 2-(4-phenylmethoxyphenyl)acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1OCC1=CC=CC=C1 OUWFDISHMBDYON-UHFFFAOYSA-N 0.000 description 4
239000002480 mineral oil Substances 0.000 description 4
235000010446 mineral oil Nutrition 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
230000009871 nonspecific binding Effects 0.000 description 4
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 4
239000010502 orange oil Substances 0.000 description 4
238000006053 organic reaction Methods 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
239000011593 sulfur Chemical group 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 4
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
HFFWXPIQBUOVFO-UHFFFAOYSA-N (4-bromophenoxy)-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC1=CC=C(Br)C=C1 HFFWXPIQBUOVFO-UHFFFAOYSA-N 0.000 description 3
CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 3
SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 3
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
DSOUTHVJSBGHPG-UHFFFAOYSA-N 1-diazonio-3-[(4-methoxyphenyl)methyl]-5-phenylpent-1-en-2-olate Chemical compound C1=CC(OC)=CC=C1CC(C(=O)C=[N+]=[N-])CCC1=CC=CC=C1 DSOUTHVJSBGHPG-UHFFFAOYSA-N 0.000 description 3
UTYYXSYJOCVTGU-UHFFFAOYSA-N 2-(4-methoxy-2-phenoxyphenyl)acetic acid Chemical compound COC1=CC=C(CC(O)=O)C(OC=2C=CC=CC=2)=C1 UTYYXSYJOCVTGU-UHFFFAOYSA-N 0.000 description 3
IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 3
GRZNODNSNCXOHE-UHFFFAOYSA-N 2-chloro-1-oxidopyridin-1-ium;hydron;chloride Chemical compound Cl.[O-][N+]1=CC=CC=C1Cl GRZNODNSNCXOHE-UHFFFAOYSA-N 0.000 description 3
HPMXFGBSGHHYPA-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonyl-(1-oxidopyridin-1-ium-2-yl)amino]propyl methanesulfonate Chemical compound CS(=O)(=O)OCCCN(C(=O)OC(C)(C)C)C1=CC=CC=[N+]1[O-] HPMXFGBSGHHYPA-UHFFFAOYSA-N 0.000 description 3
SNVBFGREAIPILK-UHFFFAOYSA-N 3-[[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]methyl]pent-4-enoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=C)=CC=2)=N1 SNVBFGREAIPILK-UHFFFAOYSA-N 0.000 description 3
NEQNHPTYRJSEGC-UHFFFAOYSA-N 4-methoxy-2-[(4-methoxyphenyl)methyl]-4-oxobutanoic acid Chemical compound COC(=O)CC(C(O)=O)CC1=CC=C(OC)C=C1 NEQNHPTYRJSEGC-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
229910010082 LiAlH Inorganic materials 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
206010029113 Neovascularisation Diseases 0.000 description 3
208000022873 Ocular disease Diseases 0.000 description 3
108010081689 Osteopontin Proteins 0.000 description 3
102000004264 Osteopontin Human genes 0.000 description 3
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
238000007259 addition reaction Methods 0.000 description 3
229910052783 alkali metal Inorganic materials 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000002491 angiogenic effect Effects 0.000 description 3
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 3
239000000969 carrier Substances 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
230000009137 competitive binding Effects 0.000 description 3
230000008878 coupling Effects 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
238000001514 detection method Methods 0.000 description 3
229940043279 diisopropylamine Drugs 0.000 description 3
VNOXYDAAZVUZDS-MRXNPFEDSA-N ethyl (3R)-4-(4-hydroxyphenyl)-3-phenylbutanoate Chemical compound C([C@H](CC(=O)OCC)C=1C=CC=CC=1)C1=CC=C(O)C=C1 VNOXYDAAZVUZDS-MRXNPFEDSA-N 0.000 description 3
OZDSWBUFECHNBL-UHFFFAOYSA-N ethyl 4-(4-hydroxyphenyl)-3-methylbut-3-enoate Chemical compound CCOC(=O)CC(C)=CC1=CC=C(O)C=C1 OZDSWBUFECHNBL-UHFFFAOYSA-N 0.000 description 3
PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 3
230000003100 immobilizing effect Effects 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
229910052740 iodine Inorganic materials 0.000 description 3
239000003446 ligand Substances 0.000 description 3
229940040692 lithium hydroxide monohydrate Drugs 0.000 description 3
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
239000012528 membrane Substances 0.000 description 3
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
DDMFLDILYVCMIW-HWKANZROSA-N methyl (e)-4-(4-methoxyphenyl)but-2-enoate Chemical compound COC(=O)\C=C\CC1=CC=C(OC)C=C1 DDMFLDILYVCMIW-HWKANZROSA-N 0.000 description 3
MHJNOSUWMQMJSD-UHFFFAOYSA-N methyl 2-[(4-hydroxy-2-methoxyphenyl)methylamino]acetate Chemical compound COC(=O)CNCC1=CC=C(O)C=C1OC MHJNOSUWMQMJSD-UHFFFAOYSA-N 0.000 description 3
OYVBPFWLDNQBAR-UHFFFAOYSA-N methyl 3-[(4-hydroxyphenyl)methyl]pent-4-enoate Chemical compound COC(=O)CC(C=C)CC1=CC=C(O)C=C1 OYVBPFWLDNQBAR-UHFFFAOYSA-N 0.000 description 3
BXJWQYPYYCKLNP-UHFFFAOYSA-N methyl 3-benzyl-4-(4-hydroxyphenyl)butanoate Chemical compound C=1C=C(O)C=CC=1CC(CC(=O)OC)CC1=CC=CC=C1 BXJWQYPYYCKLNP-UHFFFAOYSA-N 0.000 description 3
ZKDFCGHDQFQXLZ-UHFFFAOYSA-N methyl 3-cyclopropyl-4-(4-hydroxyphenyl)butanoate Chemical compound C1CC1C(CC(=O)OC)CC1=CC=C(O)C=C1 ZKDFCGHDQFQXLZ-UHFFFAOYSA-N 0.000 description 3
UZHISWLCHOMTIO-UHFFFAOYSA-N methyl 4-(4-hydroxyphenyl)butanoate Chemical compound COC(=O)CCCC1=CC=C(O)C=C1 UZHISWLCHOMTIO-UHFFFAOYSA-N 0.000 description 3
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000011164 ossification Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000003880 polar aprotic solvent Substances 0.000 description 3
238000002953 preparative HPLC Methods 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000002335 preservative effect Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000000967 suction filtration Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
KASYJFAQZXRKEJ-UHFFFAOYSA-N tert-butyl 2-[[6-(1-hydroxyethyl)pyridin-2-yl]amino]acetate Chemical compound CC(O)C1=CC=CC(NCC(=O)OC(C)(C)C)=N1 KASYJFAQZXRKEJ-UHFFFAOYSA-N 0.000 description 3
YHTZSPWLJTZRDM-UHFFFAOYSA-N tert-butyl n-(5-bromopyridin-2-yl)-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=CC=C(Br)C=N1 YHTZSPWLJTZRDM-UHFFFAOYSA-N 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
URKJIXZWGSBZBB-MRXNPFEDSA-N (3r)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-(1,3-thiazol-2-yl)butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(C[C@H](CC(O)=O)C=3SC=CN=3)=CC=2)=N1 URKJIXZWGSBZBB-MRXNPFEDSA-N 0.000 description 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
XCKXBCZYCLJDJB-UHFFFAOYSA-N 1-(1,3-benzothiazol-2-yl)-2-(4-phenylmethoxyphenyl)ethanone Chemical compound N=1C2=CC=CC=C2SC=1C(=O)CC(C=C1)=CC=C1OCC1=CC=CC=C1 XCKXBCZYCLJDJB-UHFFFAOYSA-N 0.000 description 2
PIRRWUMTIBFCCW-UHFFFAOYSA-N 1-(2-fluoro-4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(C)=O)C(F)=C1 PIRRWUMTIBFCCW-UHFFFAOYSA-N 0.000 description 2
WFWKNGZODAOLEO-UHFFFAOYSA-N 1-(4-Methoxyphenyl)-2-propanone Chemical compound COC1=CC=C(CC(C)=O)C=C1 WFWKNGZODAOLEO-UHFFFAOYSA-N 0.000 description 2
GTNVWVLCXAHTCJ-UHFFFAOYSA-N 1-(4-bromobutyl)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CCCCBr)C=C1 GTNVWVLCXAHTCJ-UHFFFAOYSA-N 0.000 description 2
LOVGXXXYYMITGI-UHFFFAOYSA-N 1-(4-methyl-1,3-thiazol-2-yl)-2-(4-phenylmethoxyphenyl)ethanone Chemical compound CC1=CSC(C(=O)CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=N1 LOVGXXXYYMITGI-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 2
JCUZLYSJHAIDAH-UHFFFAOYSA-N 2-(4-methoxy-2-phenoxyphenyl)-1-morpholin-4-ylethanethione Chemical compound C=1C=CC=CC=1OC1=CC(OC)=CC=C1CC(=S)N1CCOCC1 JCUZLYSJHAIDAH-UHFFFAOYSA-N 0.000 description 2
JABKESJVYSQBGF-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1-phenylethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)C1=CC=CC=C1 JABKESJVYSQBGF-UHFFFAOYSA-N 0.000 description 2
NRIVMXXOUOBRAG-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetaldehyde Chemical compound COC1=CC=C(CC=O)C=C1 NRIVMXXOUOBRAG-UHFFFAOYSA-N 0.000 description 2
AUWDOZOUJWEPBA-UHFFFAOYSA-N 2-(4-methoxyphenyl)ethanol Chemical compound COC1=CC=C(CCO)C=C1 AUWDOZOUJWEPBA-UHFFFAOYSA-N 0.000 description 2
IJDFWLRKIKCPGW-UHFFFAOYSA-N 2-(4-phenylmethoxyphenyl)-1-pyridin-2-ylethanone Chemical compound C=1C=CC=NC=1C(=O)CC(C=C1)=CC=C1OCC1=CC=CC=C1 IJDFWLRKIKCPGW-UHFFFAOYSA-N 0.000 description 2
FVIRBJOGMPKDHO-UHFFFAOYSA-N 2-(4-phenylmethoxyphenyl)acetaldehyde Chemical compound C1=CC(CC=O)=CC=C1OCC1=CC=CC=C1 FVIRBJOGMPKDHO-UHFFFAOYSA-N 0.000 description 2
JCUJAHLWCDISCC-UHFFFAOYSA-N 2-(4-phenylmethoxyphenyl)ethanol Chemical compound C1=CC(CCO)=CC=C1OCC1=CC=CC=C1 JCUJAHLWCDISCC-UHFFFAOYSA-N 0.000 description 2
WEMUNMQFXOILNO-UHFFFAOYSA-N 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethanol Chemical compound C1CCNC2=NC(CCO)=CC=C21 WEMUNMQFXOILNO-UHFFFAOYSA-N 0.000 description 2
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
AOCBETTUAOFOEN-UHFFFAOYSA-N 2-[6-(methylamino)pyridin-2-yl]ethanol Chemical compound CNC1=CC=CC(CCO)=N1 AOCBETTUAOFOEN-UHFFFAOYSA-N 0.000 description 2
HMLWWSKYXBGOMT-UHFFFAOYSA-N 2-benzyl-3-(4-methoxyphenyl)propanoic acid Chemical compound C1=CC(OC)=CC=C1CC(C(O)=O)CC1=CC=CC=C1 HMLWWSKYXBGOMT-UHFFFAOYSA-N 0.000 description 2
LMKOXKLMGOZPMC-UHFFFAOYSA-N 2-chloro-4-methyl-1-oxidopyridin-1-ium;hydrochloride Chemical compound Cl.CC1=CC=[N+]([O-])C(Cl)=C1 LMKOXKLMGOZPMC-UHFFFAOYSA-N 0.000 description 2
MZVSTDHRRYQFGI-UHFFFAOYSA-N 2-chloro-4-methylpyridine Chemical compound CC1=CC=NC(Cl)=C1 MZVSTDHRRYQFGI-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
IPDKGBVODWCUPX-UHFFFAOYSA-N 3-(4-bromophenyl)-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]butanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(O)=O)C=3C=CC(Br)=CC=3)=CC=2)=N1 IPDKGBVODWCUPX-UHFFFAOYSA-N 0.000 description 2
QTTQBQLTBUGHCD-UHFFFAOYSA-N 3-(pyridin-2-ylamino)propan-1-ol Chemical compound OCCCNC1=CC=CC=N1 QTTQBQLTBUGHCD-UHFFFAOYSA-N 0.000 description 2
BGBCRQSHJDEWQY-UHFFFAOYSA-N 3-cyclopropyl-1-diazonio-3-(4-methoxyphenyl)but-1-en-2-olate Chemical compound C1=CC(OC)=CC=C1C(C)(C(=O)C=[N+]=[N-])C1CC1 BGBCRQSHJDEWQY-UHFFFAOYSA-N 0.000 description 2
KUQLFLDOZKNZDN-UHFFFAOYSA-N 4-(4-ethoxy-4-oxo-2-phenylbutyl)benzoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)OCC)CC1=CC=C(C(O)=O)C=C1 KUQLFLDOZKNZDN-UHFFFAOYSA-N 0.000 description 2
GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 2
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
QMHIMXFNBOYPND-UHFFFAOYSA-N 4-methylthiazole Chemical compound CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 2
208000010392 Bone Fractures Diseases 0.000 description 2
KMKINHMKQLQSNO-UHFFFAOYSA-N Br.[O-][N+]1=CC=CC=C1NCCCBr Chemical compound Br.[O-][N+]1=CC=CC=C1NCCCBr KMKINHMKQLQSNO-UHFFFAOYSA-N 0.000 description 2
OWRNPZSGSVIKHR-UHFFFAOYSA-N C(C)(C)OC(=O)N=NC(=O)OC(C)C.C(CCC)(=O)O Chemical compound C(C)(C)OC(=O)N=NC(=O)OC(C)C.C(CCC)(=O)O OWRNPZSGSVIKHR-UHFFFAOYSA-N 0.000 description 2
AKFFEOGDSYZFBT-UHFFFAOYSA-N CC1=CC=[N+]([O-])C(NCCCO)=C1 Chemical compound CC1=CC=[N+]([O-])C(NCCCO)=C1 AKFFEOGDSYZFBT-UHFFFAOYSA-N 0.000 description 2
101150065749 Churc1 gene Proteins 0.000 description 2
108010022452 Collagen Type I Proteins 0.000 description 2
102000012422 Collagen Type I Human genes 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
201000002980 Hyperparathyroidism Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010027452 Metastases to bone Diseases 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
URDFLHZTXAMGSF-UHFFFAOYSA-N OCCCCCNC1=CC=CC=[N+]1[O-] Chemical compound OCCCCCNC1=CC=CC=[N+]1[O-] URDFLHZTXAMGSF-UHFFFAOYSA-N 0.000 description 2
208000010191 Osteitis Deformans Diseases 0.000 description 2
208000003076 Osteolysis Diseases 0.000 description 2
208000027868 Paget disease Diseases 0.000 description 2
KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
102100038239 Protein Churchill Human genes 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
238000006859 Swern oxidation reaction Methods 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000004705 aldimines Chemical class 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
150000003862 amino acid derivatives Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
239000012024 dehydrating agents‎ Substances 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
210000004268 dentin Anatomy 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
BSTAQGJAVKTSTM-DEOSSOPVSA-N ethyl (3s)-3-phenyl-4-[4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl]butanoate Chemical compound C1([C@@H](CC=2C=CC(OCCC=3N=C4NCCCC4=CC=3)=CC=2)CC(=O)OCC)=CC=CC=C1 BSTAQGJAVKTSTM-DEOSSOPVSA-N 0.000 description 2
JJXAANWAHXYCSW-IBGZPJMESA-N ethyl (3s)-4-[4-(3-aminopropoxy)phenyl]-3-phenylbutanoate Chemical compound C([C@@H](CC(=O)OCC)C=1C=CC=CC=1)C1=CC=C(OCCCN)C=C1 JJXAANWAHXYCSW-IBGZPJMESA-N 0.000 description 2
ZFAWEBMRVUWMTF-UHFFFAOYSA-N ethyl 2-[6-[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]pyridin-2-yl]acetate Chemical compound CCOC(=O)CC1=CC=CC(NCC(=O)OC(C)(C)C)=N1 ZFAWEBMRVUWMTF-UHFFFAOYSA-N 0.000 description 2
ZRKLDLAJZISBAU-UHFFFAOYSA-N ethyl 2-[benzyl-[(4-methoxyphenyl)methyl]amino]acetate Chemical compound C=1C=C(OC)C=CC=1CN(CC(=O)OCC)CC1=CC=CC=C1 ZRKLDLAJZISBAU-UHFFFAOYSA-N 0.000 description 2
HAZFZZBWLNKKQE-UHFFFAOYSA-N ethyl 3-hydroxy-4-(4-methoxyphenyl)-3-phenylbutanoate Chemical compound C=1C=CC=CC=1C(O)(CC(=O)OCC)CC1=CC=C(OC)C=C1 HAZFZZBWLNKKQE-UHFFFAOYSA-N 0.000 description 2
PYHOLLKLTJTELF-UHFFFAOYSA-N ethyl 4-(4-methoxyphenyl)-3-methylbut-3-enoate Chemical compound CCOC(=O)CC(C)=CC1=CC=C(OC)C=C1 PYHOLLKLTJTELF-UHFFFAOYSA-N 0.000 description 2
RWNIBBSFGGCIQK-UHFFFAOYSA-N ethyl 4-(4-methoxyphenyl)-3-methylbutanoate Chemical compound CCOC(=O)CC(C)CC1=CC=C(OC)C=C1 RWNIBBSFGGCIQK-UHFFFAOYSA-N 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000003163 gonadal steroid hormone Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
239000012456 homogeneous solution Substances 0.000 description 2
210000005119 human aortic smooth muscle cell Anatomy 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
206010023332 keratitis Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000005567 liquid scintillation counting Methods 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
208000029791 lytic metastatic bone lesion Diseases 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
208000027202 mammary Paget disease Diseases 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
LEFNJHVMJFCUFV-DUXPYHPUSA-N methyl (e)-4-(4-hydroxyphenyl)but-2-enoate Chemical compound COC(=O)\C=C\CC1=CC=C(O)C=C1 LEFNJHVMJFCUFV-DUXPYHPUSA-N 0.000 description 2
VEHNJODPIZBWOL-WEVVVXLNSA-N methyl (e)-4-(4-phenylmethoxyphenyl)but-2-enoate Chemical compound C1=CC(C/C=C/C(=O)OC)=CC=C1OCC1=CC=CC=C1 VEHNJODPIZBWOL-WEVVVXLNSA-N 0.000 description 2
AHANXHACCTXGAE-UHFFFAOYSA-N methyl 2-(4-hydroxy-2-phenoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(O)C=C1OC1=CC=CC=C1 AHANXHACCTXGAE-UHFFFAOYSA-N 0.000 description 2
LDKQBNAANQSXSA-UHFFFAOYSA-N methyl 2-(4-methoxy-2-phenoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(OC)C=C1OC1=CC=CC=C1 LDKQBNAANQSXSA-UHFFFAOYSA-N 0.000 description 2
OWFPSZQZAFEKHK-UHFFFAOYSA-N methyl 2-[4-tri(propan-2-yl)silyloxyphenyl]acetate Chemical compound COC(=O)CC1=CC=C(O[Si](C(C)C)(C(C)C)C(C)C)C=C1 OWFPSZQZAFEKHK-UHFFFAOYSA-N 0.000 description 2
KXRWSHXHMXMWCM-UHFFFAOYSA-N methyl 2-[n-[(4-hydroxyphenyl)methyl]anilino]acetate Chemical compound C=1C=CC=CC=1N(CC(=O)OC)CC1=CC=C(O)C=C1 KXRWSHXHMXMWCM-UHFFFAOYSA-N 0.000 description 2
DTHOJDDHHZQFDG-UHFFFAOYSA-N methyl 2-[n-[(4-methoxyphenyl)methyl]anilino]acetate Chemical compound C=1C=CC=CC=1N(CC(=O)OC)CC1=CC=C(OC)C=C1 DTHOJDDHHZQFDG-UHFFFAOYSA-N 0.000 description 2
ASGUADOJYRUTNV-UHFFFAOYSA-N methyl 3-[[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]methyl]pent-4-enoate Chemical compound CNC1=CC=CC(CCOC=2C=CC(CC(CC(=O)OC)C=C)=CC=2)=N1 ASGUADOJYRUTNV-UHFFFAOYSA-N 0.000 description 2
PRCHFYCKORQMRZ-UHFFFAOYSA-N methyl 3-benzyl-4-(4-methoxyphenyl)butanoate Chemical compound C=1C=C(OC)C=CC=1CC(CC(=O)OC)CC1=CC=CC=C1 PRCHFYCKORQMRZ-UHFFFAOYSA-N 0.000 description 2
GBFKHOMPLQCKFU-UHFFFAOYSA-N methyl 3-cyclopropyl-4-(4-methoxyphenyl)butanoate Chemical compound C1CC1C(CC(=O)OC)CC1=CC=C(OC)C=C1 GBFKHOMPLQCKFU-UHFFFAOYSA-N 0.000 description 2
RQWVXEOOYSWNFP-UHFFFAOYSA-N methyl 3-methyl-4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]but-3-enoate Chemical compound CNC1=CC=CC(CCOC=2C=CC(C=C(C)CC(=O)OC)=CC=2)=N1 RQWVXEOOYSWNFP-UHFFFAOYSA-N 0.000 description 2
GZBUAOAAFJWVAT-RXBHZZDJSA-N methyl 4-[[(2s)-3-hydroxy-1-oxo-1-phenylmethoxypropan-2-yl]amino]-4-oxo-3-[[4-tri(propan-2-yl)silyloxyphenyl]methyl]butanoate Chemical compound N([C@@H](CO)C(=O)OCC=1C=CC=CC=1)C(=O)C(CC(=O)OC)CC1=CC=C(O[Si](C(C)C)(C(C)C)C(C)C)C=C1 GZBUAOAAFJWVAT-RXBHZZDJSA-N 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
238000003801 milling Methods 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
RGVOGAUXNXMXKI-UHFFFAOYSA-N n,n-dimethyl-2-[2-(4-phenylmethoxyphenyl)acetyl]imidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=CN=C1C(=O)CC(C=C1)=CC=C1OCC1=CC=CC=C1 RGVOGAUXNXMXKI-UHFFFAOYSA-N 0.000 description 2
YRRWNBMOJMMXQY-UHFFFAOYSA-N n,n-dimethylimidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=CN=C1 YRRWNBMOJMMXQY-UHFFFAOYSA-N 0.000 description 2
SJADZVLGLQJTAO-UHFFFAOYSA-N n-[(2-methylpropan-2-yl)oxy]pyridin-2-amine Chemical compound CC(C)(C)ONC1=CC=CC=N1 SJADZVLGLQJTAO-UHFFFAOYSA-N 0.000 description 2
NFZWIMOIORHGEH-UHFFFAOYSA-N n-methoxy-n-methyl-2-(4-phenylmethoxyphenyl)acetamide Chemical compound C1=CC(CC(=O)N(C)OC)=CC=C1OCC1=CC=CC=C1 NFZWIMOIORHGEH-UHFFFAOYSA-N 0.000 description 2
125000001624 naphthyl group Chemical group 0.000 description 2
230000014399 negative regulation of angiogenesis Effects 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
TXSXJLMEOQAASX-UHFFFAOYSA-N phenyl but-2-enoate Chemical compound CC=CC(=O)OC1=CC=CC=C1 TXSXJLMEOQAASX-UHFFFAOYSA-N 0.000 description 2
DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
229940049953 phenylacetate Drugs 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
229950009215 phenylbutanoic acid Drugs 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
229940063179 platinol Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
238000011552 rat model Methods 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
239000013557 residual solvent Substances 0.000 description 2
238000002390 rotary evaporation Methods 0.000 description 2
238000007127 saponification reaction Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
GIYSIHYOVYXTIA-UHFFFAOYSA-N tert-butyl 2-[(6-methylpyridin-2-yl)amino]acetate Chemical compound CC1=CC=CC(NCC(=O)OC(C)(C)C)=N1 GIYSIHYOVYXTIA-UHFFFAOYSA-N 0.000 description 2
BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
CHWMFCCGEWQABK-UHFFFAOYSA-N tert-butyl 7-methyl-3,4-dihydro-2h-1,8-naphthyridine-1-carboxylate Chemical compound C1CCN(C(=O)OC(C)(C)C)C2=NC(C)=CC=C21 CHWMFCCGEWQABK-UHFFFAOYSA-N 0.000 description 2
LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical class CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 2
FOBYZCVTICTNMG-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)-n-(1-oxidopyridin-1-ium-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)N(CCCO)C1=CC=CC=[N+]1[O-] FOBYZCVTICTNMG-UHFFFAOYSA-N 0.000 description 2
CKXAMCSVTNPSCZ-UHFFFAOYSA-N tert-butyl n-(5-bromopyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(Br)C=N1 CKXAMCSVTNPSCZ-UHFFFAOYSA-N 0.000 description 2
PFSSGFHKAYKYKH-UHFFFAOYSA-N tert-butyl n-(5-ethenylpyridin-2-yl)-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=CC=C(C=C)C=N1 PFSSGFHKAYKYKH-UHFFFAOYSA-N 0.000 description 2
XSVAARVWQDEAEL-UHFFFAOYSA-N tert-butyl n-(6-methylpyridin-2-yl)carbamate Chemical compound CC1=CC=CC(NC(=O)OC(C)(C)C)=N1 XSVAARVWQDEAEL-UHFFFAOYSA-N 0.000 description 2
LNGSPBARAFUWCQ-UHFFFAOYSA-N tert-butyl n-[2-(pyridin-2-ylamino)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNC1=CC=CC=N1 LNGSPBARAFUWCQ-UHFFFAOYSA-N 0.000 description 2
PEVCOUVEEKVDPY-UHFFFAOYSA-N tert-butyl n-[4-(4-aminophenyl)butyl]-n-pyridin-2-ylcarbamate Chemical compound C=1C=CC=NC=1N(C(=O)OC(C)(C)C)CCCCC1=CC=C(N)C=C1 PEVCOUVEEKVDPY-UHFFFAOYSA-N 0.000 description 2
TUUMNHGLJLFEDM-UHFFFAOYSA-N tert-butyl n-[4-(4-nitrophenyl)butyl]-n-pyridin-2-ylcarbamate Chemical compound C=1C=CC=NC=1N(C(=O)OC(C)(C)C)CCCCC1=CC=C([N+]([O-])=O)C=C1 TUUMNHGLJLFEDM-UHFFFAOYSA-N 0.000 description 2
BIRHFCQAQSPKSN-UHFFFAOYSA-N tert-butyl n-[5-(1-hydroxyethyl)pyridin-2-yl]-n-methylcarbamate Chemical compound CC(O)C1=CC=C(N(C)C(=O)OC(C)(C)C)N=C1 BIRHFCQAQSPKSN-UHFFFAOYSA-N 0.000 description 2
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229950003937 tolonium Drugs 0.000 description 2
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
238000001665 trituration Methods 0.000 description 2
239000008096 xylene Substances 0.000 description 2
150000003738 xylenes Chemical class 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 1
UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 1
YUJZXXIRMQTZPV-UHFFFAOYSA-N (4-hydroxyphenyl) butanoate Chemical compound CCCC(=O)OC1=CC=C(O)C=C1 YUJZXXIRMQTZPV-UHFFFAOYSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
OTKCEEWUXHVZQI-UHFFFAOYSA-N 1,2-diphenylethanone Chemical class C=1C=CC=CC=1C(=O)CC1=CC=CC=C1 OTKCEEWUXHVZQI-UHFFFAOYSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
NEDRYPNPIWUFAX-UHFFFAOYSA-N 1,3-oxazol-2-yl butanoate Chemical compound CCCC(=O)OC1=NC=CO1 NEDRYPNPIWUFAX-UHFFFAOYSA-N 0.000 description 1
PWCPEULDILQBKI-UHFFFAOYSA-N 1,3-thiazol-2-yl butanoate Chemical compound CCCC(=O)OC1=NC=CS1 PWCPEULDILQBKI-UHFFFAOYSA-N 0.000 description 1
UOWLNAWSJHCURI-UHFFFAOYSA-N 1-(methylamino)-1-pyridin-2-ylethanol Chemical compound CNC(C)(O)C1=CC=CC=N1 UOWLNAWSJHCURI-UHFFFAOYSA-N 0.000 description 1
WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical group [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
IRBRQQNLZOUINR-UHFFFAOYSA-N 1-diazonio-3-(4-methoxyphenyl)-3-methyl-4-phenylbut-1-en-2-olate Chemical compound C1=CC(OC)=CC=C1C(C)(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 IRBRQQNLZOUINR-UHFFFAOYSA-N 0.000 description 1
HYLKZTUNVSHVHW-UHFFFAOYSA-N 1-diazonio-4-(4-methoxyphenyl)-3-thiophen-2-ylbut-1-en-2-olate Chemical compound C1=CC(OC)=CC=C1CC(C(=O)C=[N+]=[N-])C1=CC=CS1 HYLKZTUNVSHVHW-UHFFFAOYSA-N 0.000 description 1
SRKQWNFPTBNUKE-UHFFFAOYSA-N 1-methyl-1,2-dinitroguanidine Chemical compound [O-][N+](=O)N(C)\C(N)=N/[N+]([O-])=O SRKQWNFPTBNUKE-UHFFFAOYSA-N 0.000 description 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 description 1
XSJLEHRRPHCAQC-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)butanoic acid Chemical compound CCC(C(O)=O)C1=NC=CS1 XSJLEHRRPHCAQC-UHFFFAOYSA-N 0.000 description 1
MHWKUYDFZRLARI-UHFFFAOYSA-N 2-(4-methoxyphenoxy)-1-phenylethanone Chemical compound C1=CC(OC)=CC=C1OCC(=O)C1=CC=CC=C1 MHWKUYDFZRLARI-UHFFFAOYSA-N 0.000 description 1
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
DLBWIZCXAUJCEA-UHFFFAOYSA-N 2-[4-tri(propan-2-yl)silyloxyphenyl]acetaldehyde Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC1=CC=C(CC=O)C=C1 DLBWIZCXAUJCEA-UHFFFAOYSA-N 0.000 description 1
BUORQYNZKSPRED-UHFFFAOYSA-N 2-[4-tri(propan-2-yl)silyloxyphenyl]ethanol Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC1=CC=C(CCO)C=C1 BUORQYNZKSPRED-UHFFFAOYSA-N 0.000 description 1
150000003930 2-aminopyridines Chemical class 0.000 description 1
PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 1
WYEXGNPNDCBAGC-UHFFFAOYSA-N 2-cyclopropyl-3-(4-methoxyphenyl)propanoic acid Chemical compound C1=CC(OC)=CC=C1CC(C(O)=O)C1CC1 WYEXGNPNDCBAGC-UHFFFAOYSA-N 0.000 description 1
FSWRUYCICUXURT-UHFFFAOYSA-N 2-methyl-1,8-naphthyridine Chemical compound C1=CC=NC2=NC(C)=CC=C21 FSWRUYCICUXURT-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
ZCJLOOJRNPHKAV-UHFFFAOYSA-N 3-(furan-2-yl)prop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CO1 ZCJLOOJRNPHKAV-UHFFFAOYSA-N 0.000 description 1
NPFZAYYOIXVIIM-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonyl-pyridin-2-ylamino]propyl methanesulfonate Chemical compound CS(=O)(=O)OCCCN(C(=O)OC(C)(C)C)C1=CC=CC=N1 NPFZAYYOIXVIIM-UHFFFAOYSA-N 0.000 description 1
CXPGMUWXMIRPGU-UHFFFAOYSA-N 3-[(4-methylpyridin-2-yl)amino]propan-1-ol Chemical compound CC1=CC=NC(NCCCO)=C1 CXPGMUWXMIRPGU-UHFFFAOYSA-N 0.000 description 1
UWDDZMZGEOUJFQ-UHFFFAOYSA-N 4-(1-ethoxy-1-oxo-3-phenylbutan-2-yl)benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1C(C(=O)OCC)C(C)C1=CC=CC=C1 UWDDZMZGEOUJFQ-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
MFYJBAQONVFIFC-UHFFFAOYSA-N 4-(4-nitrophenyl)butan-1-ol Chemical compound OCCCCC1=CC=C([N+]([O-])=O)C=C1 MFYJBAQONVFIFC-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 1
101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 1
238000006218 Arndt-Eistert homologation reaction Methods 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
LFHAOZGMUCCTLK-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC=C(C=C1)CC(=O)C=1SC=CN1.COC1=CC=C(C=C1)CC(C)=O Chemical group C(C1=CC=CC=C1)OC1=CC=C(C=C1)CC(=O)C=1SC=CN1.COC1=CC=C(C=C1)CC(C)=O LFHAOZGMUCCTLK-UHFFFAOYSA-N 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
241000252095 Congridae Species 0.000 description 1
229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
229930195711 D-Serine Natural products 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
206010017076 Fracture Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
101000613820 Homo sapiens Osteopontin Proteins 0.000 description 1
101000703512 Homo sapiens Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
101000803709 Homo sapiens Vitronectin Proteins 0.000 description 1
208000037147 Hypercalcaemia Diseases 0.000 description 1
206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
238000006751 Mitsunobu reaction Methods 0.000 description 1
101100015391 Mus musculus Ralgds gene Proteins 0.000 description 1
NPKSPKHJBVJUKB-UHFFFAOYSA-N N-phenylglycine Chemical compound OC(=O)CNC1=CC=CC=C1 NPKSPKHJBVJUKB-UHFFFAOYSA-N 0.000 description 1
LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 1
208000034827 Neointima Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
241001536563 Panus Species 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000002154 Pterygium Diseases 0.000 description 1
101001121466 Rattus norvegicus Osteopontin Proteins 0.000 description 1
101000703459 Rattus norvegicus Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
229910004298 SiO 2 Inorganic materials 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
208000001435 Thromboembolism Diseases 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
238000005672 Willgerodt-Kindler rearrangement reaction Methods 0.000 description 1
238000007239 Wittig reaction Methods 0.000 description 1
SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
HUXIAXQSTATULQ-UHFFFAOYSA-N [6-bromo-3-[(2-methoxyphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1OP(O)(O)=O HUXIAXQSTATULQ-UHFFFAOYSA-N 0.000 description 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
IYMFCVFHHMTEQJ-UHFFFAOYSA-N [N+](=[N-])=CC(C(CC1=CC=C(C=C1)OC)CCC1=CC=CC=C1)=O.[N+](=[N-])=CC(C(C)(CC1=CC=CC=C1)C1=CC=C(C=C1)OC)=O Chemical group [N+](=[N-])=CC(C(CC1=CC=C(C=C1)OC)CCC1=CC=CC=C1)=O.[N+](=[N-])=CC(C(C)(CC1=CC=CC=C1)C1=CC=C(C=C1)OC)=O IYMFCVFHHMTEQJ-UHFFFAOYSA-N 0.000 description 1
WMYKEEYRBMHIRD-UHFFFAOYSA-N [O-][N+]1=CC=CC=C1NCCCBr Chemical compound [O-][N+]1=CC=CC=C1NCCCBr WMYKEEYRBMHIRD-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
150000000475 acetylene derivatives Chemical class 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
102000019997 adhesion receptor Human genes 0.000 description 1
108010013985 adhesion receptor Proteins 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
206010064930 age-related macular degeneration Diseases 0.000 description 1
238000005575 aldol reaction Methods 0.000 description 1
229940062527 alendronate Drugs 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910001508 alkali metal halide Inorganic materials 0.000 description 1
150000008045 alkali metal halides Chemical class 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
230000007815 allergy Effects 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229950011175 aminopicoline Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002257 antimetastatic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
150000003934 aromatic aldehydes Chemical class 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
150000008038 benzoazepines Chemical class 0.000 description 1
MGZWCDQAKCHOBX-FVGYRXGTSA-N benzyl (2s)-2-amino-3-hydroxypropanoate;hydrochloride Chemical compound Cl.OC[C@H](N)C(=O)OCC1=CC=CC=C1 MGZWCDQAKCHOBX-FVGYRXGTSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
238000007068 beta-elimination reaction Methods 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002617 bone density conservation agent Substances 0.000 description 1
229940112869 bone morphogenetic protein Drugs 0.000 description 1
230000010072 bone remodeling Effects 0.000 description 1
UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
239000011449 brick Substances 0.000 description 1
XNNQFQFUQLJSQT-UHFFFAOYSA-N bromo(trichloro)methane Chemical compound ClC(Cl)(Cl)Br XNNQFQFUQLJSQT-UHFFFAOYSA-N 0.000 description 1
KOAVNZURYJRNDR-UHFFFAOYSA-N bromoethene;magnesium Chemical compound [Mg].BrC=C KOAVNZURYJRNDR-UHFFFAOYSA-N 0.000 description 1
OWVBKVUUDMFVCR-UHFFFAOYSA-M bromozinc(1+);tert-butyl acetate Chemical compound Br[Zn+].CC(C)(C)OC([CH2-])=O OWVBKVUUDMFVCR-UHFFFAOYSA-M 0.000 description 1
229940045348 brown mixture Drugs 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000021523 carboxylation Effects 0.000 description 1
238000006473 carboxylation reaction Methods 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000003352 cell adhesion assay Methods 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 1
229940096422 collagen type i Drugs 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
150000001987 diarylethers Chemical class 0.000 description 1
XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
108010025752 echistatin Proteins 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000012039 electrophile Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
150000002168 ethanoic acid esters Chemical class 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
NDPOZXUPRVAMTH-QFIPXVFZSA-N ethyl (3s)-4-[4-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propoxy]phenyl]-3-phenylbutanoate Chemical compound C([C@@H](CC(=O)OCC)C=1C=CC=CC=1)C1=CC=C(OCCCNC(=O)OC(C)(C)C)C=C1 NDPOZXUPRVAMTH-QFIPXVFZSA-N 0.000 description 1
XQBHPXFYDNWPHL-ZHACJKMWSA-N ethyl (e)-4-(4-methoxyphenyl)-3-methylbut-2-enoate Chemical compound CCOC(=O)\C=C(/C)CC1=CC=C(OC)C=C1 XQBHPXFYDNWPHL-ZHACJKMWSA-N 0.000 description 1
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
QSUANHXENVRFDN-UHFFFAOYSA-N ethyl 2-thiophen-2-ylacetate Chemical compound CCOC(=O)CC1=CC=CS1 QSUANHXENVRFDN-UHFFFAOYSA-N 0.000 description 1
KKEDYWDBENRGOT-UHFFFAOYSA-N ethyl 4-[4-[2-[6-(methylamino)pyridin-2-yl]ethoxy]phenyl]-3-pyridin-2-ylbutanoate Chemical compound C=1C=CC=NC=1C(CC(=O)OCC)CC(C=C1)=CC=C1OCCC1=CC=CC(NC)=N1 KKEDYWDBENRGOT-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
201000010934 exostosis Diseases 0.000 description 1
KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000002223 garnet Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
108010045624 glutamyl-lysyl-alanyl-histidyl-aspartyl-glycyl-glycyl-arginine Proteins 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
235000013905 glycine and its sodium salt Nutrition 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
230000005484 gravity Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000010440 gypsum Substances 0.000 description 1
229910052602 gypsum Inorganic materials 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000000148 hypercalcaemia Effects 0.000 description 1
201000010930 hyperostosis Diseases 0.000 description 1
239000005457 ice water Substances 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000000752 ionisation method Methods 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
108010034897 lentil lectin Proteins 0.000 description 1
239000011968 lewis acid catalyst Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
UDWJEJINASVQGJ-UHFFFAOYSA-M magnesium;1-methanidyl-4-methoxybenzene;chloride Chemical compound [Mg+2].[Cl-].COC1=CC=C([CH2-])C=C1 UDWJEJINASVQGJ-UHFFFAOYSA-M 0.000 description 1
RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
KNKIXYMOHMYZJR-UHFFFAOYSA-N methyl 2-thiophen-2-ylacetate Chemical compound COC(=O)CC1=CC=CS1 KNKIXYMOHMYZJR-UHFFFAOYSA-N 0.000 description 1
FLOILVFHEPWDQW-UHFFFAOYSA-N methyl 4-(4-hydroxyphenyl)-3-phenylbutanoate Chemical compound C=1C=CC=CC=1C(CC(=O)OC)CC1=CC=C(O)C=C1 FLOILVFHEPWDQW-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
210000004925 microvascular endothelial cell Anatomy 0.000 description 1
238000010232 migration assay Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
HWWVAHCWJLGKLW-UHFFFAOYSA-N n,n-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
201000003142 neovascular glaucoma Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
AKRYBBWYDSDZHG-UHFFFAOYSA-N nitrosobis(2-oxopropyl)amine Chemical compound CC(=O)CN(N=O)CC(C)=O AKRYBBWYDSDZHG-UHFFFAOYSA-N 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940100691 oral capsule Drugs 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
125000001979 organolithium group Chemical group 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
229950008017 ormaplatin Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
208000005368 osteomalacia Diseases 0.000 description 1
208000002865 osteopetrosis Diseases 0.000 description 1
150000007978 oxazole derivatives Chemical class 0.000 description 1
150000002916 oxazoles Chemical class 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
229940100595 phenylacetaldehyde Drugs 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
CFSVEFLOHSULPY-UHFFFAOYSA-N pyridin-2-yl butanoate Chemical compound CCCC(=O)OC1=CC=CC=N1 CFSVEFLOHSULPY-UHFFFAOYSA-N 0.000 description 1
ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
150000003254 radicals Chemical group 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
238000007790 scraping Methods 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
230000015590 smooth muscle cell migration Effects 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 1
PHPURFGJZBWWEK-UHFFFAOYSA-N tert-butyl n-(3-hydroxypropyl)-n-pyridin-2-ylcarbamate Chemical compound CC(C)(C)OC(=O)N(CCCO)C1=CC=CC=N1 PHPURFGJZBWWEK-UHFFFAOYSA-N 0.000 description 1
ORUGTGTZBRUQIT-UHFFFAOYSA-N tert-butyl n-pyridin-2-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=N1 ORUGTGTZBRUQIT-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
230000008467 tissue growth Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000009901 transfer hydrogenation reaction Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
LGSAOJLQTXCYHF-UHFFFAOYSA-N tri(propan-2-yl)-tri(propan-2-yl)silyloxysilane Chemical compound CC(C)[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)C(C)C LGSAOJLQTXCYHF-UHFFFAOYSA-N 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000012855 volatile organic compound Substances 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK1329-2000A 1998-03-10 1999-03-10 Antagonisty vitronektínového receptora, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty SK13292000A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7761098P	1998-03-10	1998-03-10
US9606398P	1998-08-11	1998-08-11
PCT/US1999/005232 WO1999045927A1 (en)	1998-03-10	1999-03-10	Vitronectin receptor antagonists

Publications (1)

Publication Number	Publication Date
SK13292000A3 true SK13292000A3 (sk)	2001-06-11

Family

ID=26759473

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1329-2000A SK13292000A3 (sk)	1998-03-10	1999-03-10	Antagonisty vitronektínového receptora, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty

Country Status (24)

Country	Link
EP (1)	EP1061921A4 (id)
JP (1)	JP2002506033A (id)
KR (1)	KR20010041812A (id)
CN (1)	CN1299282A (id)
AP (1)	AP2000001898A0 (id)
AR (1)	AR015241A1 (id)
AU (1)	AU758498B2 (id)
BG (1)	BG104824A (id)
BR (1)	BR9908636A (id)
CA (1)	CA2323208A1 (id)
CO (1)	CO5080762A1 (id)
DZ (1)	DZ2741A1 (id)
EA (1)	EA200000921A1 (id)
HU (1)	HUP0101143A3 (id)
ID (1)	ID26223A (id)
IL (1)	IL138245A0 (id)
NO (1)	NO20004503L (id)
OA (1)	OA12189A (id)
PE (1)	PE20000323A1 (id)
PL (1)	PL342881A1 (id)
SK (1)	SK13292000A3 (id)
TR (1)	TR200002625T2 (id)
UY (2)	UY25421A1 (id)
WO (1)	WO1999045927A1 (id)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19939981A1 (de) *	1999-08-24	2001-03-01	Merck Patent Gmbh	Neue Inhibitoren des Integrins alphavß3
DE19939980A1 (de) *	1999-08-24	2001-03-01	Merck Patent Gmbh	Inhibitoren des Integrins alphavbeta¶3¶
EG24179A (en) *	1999-09-07	2008-09-28	Smithkline Beecham Corp	Vitronectin receptor antagonists
US6881736B1 (en)	1999-09-07	2005-04-19	Smithkline Beecham Corporation	Vitronectin receptor antagonists
US6448278B2 (en)	1999-12-23	2002-09-10	Pfizer Inc.	Procollagen C-proteinase inhibitors
GB9930570D0 (en) *	1999-12-23	2000-02-16	Pfizer Ltd	Therapy
FR2808798A1 (fr) *	2000-05-09	2001-11-16	Hoechst Marion Roussel Inc	Nouveaux derives antagonistes du recepteur de la vitronectine
AU2001269821A1 (en)	2000-06-15	2001-12-24	Barbara Chen	Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en)	2001-08-29	2003-03-11	Pharmacia Corporation	Gem-substituted αvβ3 antagonists
US6645993B2 (en)	2001-03-30	2003-11-11	Warner-Lambert Company	3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en)	2002-04-05	2004-04-06	Warner-Lambert Company, Llc	Antidiabetic agents
US20070275956A1 (en) *	2003-10-14	2007-11-29	Lohray Braj B	Novel Heterocyclic Compounds
RU2367661C2 (ru) *	2004-03-05	2009-09-20	Тайсо Фармасьютикал Ко., Лтд.	Производные тиазола
UA87854C2 (en)	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
BRPI0610506A2 (pt)	2005-04-20	2010-06-29	Johnson & Johnson	moduladores de trombina de n-óxidos de piridina fluorados e processo para n-oxidação de heteroarilas contendo nitrogênio
PL3040329T3 (pl) *	2013-08-29	2019-04-30	Kyoto Pharma Ind	Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości
SI3050878T1 (sl)	2013-09-24	2022-01-31	Fujifilm Corporation	Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te
ES2864079T3 (es)	2014-05-30	2021-10-13	Pfizer	Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2023275715A1 (en)	2021-06-30	2023-01-05	Pfizer Inc.	Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ203898A3 (cs) *	1995-12-29	1999-03-17	Smithkline Beecham Corporation	Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
WO1997024122A1 (en) *	1995-12-29	1997-07-10	Smithkline Beecham Corporation	Vitronectin receptor antagonists

1999
- 1999-03-10 CN CN99805833A patent/CN1299282A/zh active Pending
- 1999-03-10 WO PCT/US1999/005232 patent/WO1999045927A1/en not_active Ceased
- 1999-03-10 EP EP99909952A patent/EP1061921A4/en not_active Withdrawn
- 1999-03-10 ID IDW20001737A patent/ID26223A/id unknown
- 1999-03-10 DZ DZ990042A patent/DZ2741A1/xx active
- 1999-03-10 UY UY25421A patent/UY25421A1/es unknown
- 1999-03-10 CO CO99014712A patent/CO5080762A1/es unknown
- 1999-03-10 OA OA00000248A patent/OA12189A/en unknown
- 1999-03-10 CA CA002323208A patent/CA2323208A1/en not_active Abandoned
- 1999-03-10 BR BR9908636-0A patent/BR9908636A/pt not_active Application Discontinuation
- 1999-03-10 KR KR1020007010091A patent/KR20010041812A/ko not_active Withdrawn
- 1999-03-10 SK SK1329-2000A patent/SK13292000A3/sk unknown
- 1999-03-10 JP JP2000535342A patent/JP2002506033A/ja not_active Withdrawn
- 1999-03-10 HU HU0101143A patent/HUP0101143A3/hu unknown
- 1999-03-10 AU AU29033/99A patent/AU758498B2/en not_active Ceased
- 1999-03-10 IL IL13824599A patent/IL138245A0/xx unknown
- 1999-03-10 AR ARP990101019A patent/AR015241A1/es not_active Application Discontinuation
- 1999-03-10 AP APAP/P/2000/001898A patent/AP2000001898A0/en unknown
- 1999-03-10 PE PE1999000188A patent/PE20000323A1/es not_active Application Discontinuation
- 1999-03-10 PL PL99342881A patent/PL342881A1/xx unknown
- 1999-03-10 EA EA200000921A patent/EA200000921A1/ru unknown
- 1999-03-10 TR TR2000/02625T patent/TR200002625T2/xx unknown
- 1999-05-19 UY UY25519A patent/UY25519A1/es unknown
2000
- 2000-09-08 NO NO20004503A patent/NO20004503L/no unknown
- 2000-10-03 BG BG104824A patent/BG104824A/xx unknown

Also Published As

Publication number	Publication date
AU758498B2 (en)	2003-03-20
PE20000323A1 (es)	2000-05-24
BG104824A (en)	2001-05-31
PL342881A1 (en)	2001-07-16
WO1999045927A1 (en)	1999-09-16
DZ2741A1 (fr)	2003-09-08
JP2002506033A (ja)	2002-02-26
HUP0101143A3 (en)	2002-12-28
TR200002625T2 (tr)	2000-12-21
UY25519A1 (es)	1999-12-13
NO20004503D0 (no)	2000-09-08
AR015241A1 (es)	2001-04-18
HUP0101143A2 (hu)	2001-08-28
OA12189A (en)	2006-05-09
IL138245A0 (en)	2001-10-31
EP1061921A4 (en)	2005-03-30
CO5080762A1 (es)	2001-09-25
CN1299282A (zh)	2001-06-13
AP2000001898A0 (en)	2000-09-30
BR9908636A (pt)	2002-01-08
EA200000921A1 (ru)	2001-04-23
CA2323208A1 (en)	1999-09-16
ID26223A (id)	2000-12-07
NO20004503L (no)	2000-10-10
EP1061921A1 (en)	2000-12-27
AU2903399A (en)	1999-09-27
KR20010041812A (ko)	2001-05-25
UY25421A1 (es)	2001-07-31

Publication	Publication Date	Title
SK13292000A3 (sk)	2001-06-11	Antagonisty vitronektínového receptora, spôsob ich výroby, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
EP0957917B1 (en)	2005-12-07	Vitronectin receptor antagonists
KR19990076878A (ko)	1999-10-25	비트로넥틴 수용체 길항제
WO1999015508A1 (en)	1999-04-01	Vitronectin receptor antagonists
US6495560B1 (en)	2002-12-17	Vitronectin receptor antagonist
JP4685307B2 (ja)	2011-05-18	ビトロネクチン受容体アンタゴニスト
US20020147334A1 (en)	2002-10-10	Vitronectin Receptor Antagonists
US6881736B1 (en)	2005-04-19	Vitronectin receptor antagonists
US6458814B1 (en)	2002-10-01	Vitronectin receptor antagonists
MXPA00008847A (en)	2001-09-07	Vitronectin receptor antagonists
CZ20003289A3 (cs)	2001-03-14	Antagonisté receptoru vitronektinu
MXPA00002700A (en)	2002-03-26	Vitronectin receptor antagonists
HK1023730B (en)	2006-08-11	Vitronectin receptor antagonists